Tumor-associated antigen presented by major histocompatibility complex and recognized by T cell receptor (None that is standard; occasionally abbreviated as TAA-MHC/TCR complex in publications, but no universally accepted abbreviation.)

The **tumor-associated antigen via MHC/TCR interface** is the molecular interaction whereby peptides derived from tumor-associated antigens are presented by major histocompatibility complex (MHC) molecules on the surface of tumor cells and recognized by T cell receptors (TCRs) on immune cells. This interaction controls the activation of T cells against cancer and is fundamental for cell-mediated tumor immunity. Therapeutic strategies, such as adoptive T cell therapy (TCR-T), TCR-fusion proteins (e.g., tebentafusp), and tumor vaccines, are designed to target this interface for selective destruction of tumor cells. Challenges include tumor immune evasion, variable antigen presentation, potential toxicity, and the diversity of MHC/TCR recognition biology[1][2][4][7][10].

Other names

Tumor antigen-MHC/TCR interfaceTCR-peptide/MHC interactionTumor antigen presentation via MHC to TCRpMHC-TCR complex

Recognition and lysis of cells presenting antigenic peptides via MHC by engineered T cells (TCR-T); Redirection of T cells to tumor cells via bispecific fusion proteins or ImmTACs; Immune stimulation by vaccination with tumor antigen peptides